DTP|01 |Inactive|DTAP|107 OPV|02 |Inactive|POLIO|89 MMR|03 |Active|MMR|03 M/R|04 |Inactive|MMR|03 measles|05 |Inactive|MMR|03 rubella|06 |Inactive|MMR|03 mumps|07 |Inactive|MMR|03 Hep B, adolescent or pediatric|08 |Active|HepB|45 Td (adult), 2 Lf tetanus toxoid, preservative free, adsorbed|09 |Active|Td|139 IPV|10 |Active|POLIO|89 pneumococcal conjugate PCV 7|100 |Inactive|PneumoPCV|152 typhoid, ViCPs|101 |Active|TYPHOID|91 DTP-Hib-Hep B|102 |Non-US|HepB|45 DTP-Hib-Hep B|102 |Non-US|DTAP|107 DTP-Hib-Hep B|102 |Non-US|HIB|17 meningococcal C conjugate|103 |Inactive|MENING|108 Hep A-Hep B|104 |Active|HepA|85 Hep A-Hep B|104 |Active|HepB|45 vaccinia (smallpox) diluted|105 |Inactive|Orthopoxvirus|75 DTaP, 5 pertussis antigens|106 |Active|DTAP|107 DTaP, unspecified formulation|107 |Inactive|DTAP|107 meningococcal ACWY, unspecified formulation|108 |Inactive|MENING|108 pneumococcal, unspecified formulation|109 |Inactive|PneumoPCV|152 pneumococcal, unspecified formulation|109 |Inactive|PneumoPPV|33 DTaP-Hep B-IPV|110 |Active|DTAP|107 DTaP-Hep B-IPV|110 |Active|HepB|45 DTaP-Hep B-IPV|110 |Active|POLIO|89 influenza, live, intranasal|111 |Inactive|FLU|88 Td (adult), 5 Lf tetanus toxoid, preservative free, adsorbed|113 |Active|Td|139 meningococcal MCV4P|114 |Active|MENING|108 Tdap|115 |Active|TDAP|115 rotavirus, pentavalent|116 |Active|ROTAVIRUS|122 HPV, bivalent|118 |Inactive|HPV|137 rotavirus, monovalent|119 |Active|ROTAVIRUS|122 DTaP-Hib-IPV|120 |Active|DTAP|107 DTaP-Hib-IPV|120 |Active|POLIO|89 DTaP-Hib-IPV|120 |Active|HIB|17 zoster live|121 |Active|ZOSTER|188 rotavirus, unspecified formulation|122 |Inactive|ROTAVIRUS|122 influenza, H5N1-1203|123 |Inactive|H5N1 flu|123 Novel Influenza-H1N1-09, nasal|125 |Inactive|H1N1 flu|128 Novel influenza-H1N1-09, preservative-free|126 |Inactive|H1N1 flu|128 Novel influenza-H1N1-09|127 |Inactive|H1N1 flu|128 Novel Influenza-H1N1-09, all formulations|128 |Inactive|H1N1 flu|128 Japanese Encephalitis, unspecified formulation|129 |Inactive|Japanese encephalitis|129 DTaP-IPV|130 |Active|POLIO|89 DTaP-IPV|130 |Active|DTAP|107 DTaP-IPV-HIB-HEP B, historical|132 |Inactive|POLIO|89 DTaP-IPV-HIB-HEP B, historical|132 |Inactive|HIB|17 DTaP-IPV-HIB-HEP B, historical|132 |Inactive|DTAP|107 DTaP-IPV-HIB-HEP B, historical|132 |Inactive|HepB|45 Pneumococcal conjugate PCV 13|133 |Active|PneumoPCV|152 Japanese Encephalitis IM|134 |Active|Japanese encephalitis|129 Influenza, high dose seasonal|135 |Active|FLU|88 Meningococcal MCV4O|136 |Active|MENING|108 HPV, unspecified formulation|137 |Inactive|HPV|137 Td (adult)|138 |Inactive|Td|139 Td(adult) unspecified formulation|139 |Inactive|Td|139 Influenza, seasonal, injectable, preservative free|140 |Inactive|FLU|88 Influenza, seasonal, injectable|141 |Active|FLU|88 Adenovirus types 4 and 7|143 |Active|ADENO|82 influenza, seasonal, intradermal, preservative free|144 |Inactive|FLU|88 DTaP,IPV,Hib,HepB|146 |Active|POLIO|89 DTaP,IPV,Hib,HepB|146 |Active|HepB|45 DTaP,IPV,Hib,HepB|146 |Active|DTAP|107 DTaP,IPV,Hib,HepB|146 |Active|HIB|17 meningococcal MCV4, unspecified formulation|147 |Inactive|MENING|108 Meningococcal C/Y-HIB PRP|148 |Inactive|MENING|108 Meningococcal C/Y-HIB PRP|148 |Inactive|HIB|17 influenza, live, intranasal, quadrivalent|149 |Active|FLU|88 influenza, split (incl. purified surface antigen)|15 |Inactive|FLU|88 influenza, injectable, quadrivalent, preservative free|150 |Active|FLU|88 influenza nasal, unspecified formulation|151 |Inactive|FLU|88 Pneumococcal Conjugate, unspecified formulation|152 |Inactive|PneumoPCV|152 Influenza, injectable, MDCK, preservative free|153 |Inactive|FLU|88 influenza, recombinant, injectable, preservative free|155 |Active|FLU|88 influenza, injectable, quadrivalent|158 |Active|FLU|88 influenza, whole|16 |Inactive|FLU|88 Influenza A monovalent (H5N1), ADJUVANTED-2013|160 |Active|H5N1 flu|123 Influenza, injectable,quadrivalent, preservative free, pediatric|161 |Active|FLU|88 meningococcal B, recombinant|162 |Active|MeningB|164 meningococcal B, OMV|163 |Active|MeningB|164 meningococcal B, unspecified|164 |Inactive|MeningB|164 HPV9|165 |Active|HPV|137 influenza, intradermal, quadrivalent, preservative free|166 |Inactive|FLU|88 influenza, trivalent, adjuvanted|168 |Active|FLU|88 Hib, unspecified formulation|17 |Inactive|HIB|17 DTAP/IPV/HIB - non-US|170 |Non-US|HIB|17 DTAP/IPV/HIB - non-US|170 |Non-US|DTAP|107 DTAP/IPV/HIB - non-US|170 |Non-US|POLIO|89 Influenza, injectable, MDCK, preservative free, quadrivalent|171 |Active|FLU|88 cholera, WC-rBS|172 |Non-US|cholera|26 cholera, BivWC|173 |Non-US|cholera|26 cholera, live attenuated|174 |Active|cholera|26 Rabies - IM Diploid cell culture|175 |Active|RABIES|90 Rabies - IM fibroblast culture|176 |Active|RABIES|90 PCV10|177 |Non-US|PneumoPCV|152 rabies, intramuscular injection|18 |Inactive|RABIES|90 Yellow fever vaccine live - alt|183 |Active|YELLOWFEVER|184 Yellow fever, unspecified|184 |Inactive|YELLOWFEVER|184 influenza, recombinant, quadrivalent,injectable, preservative free|185 |Active|FLU|88 Influenza, injectable, MDCK, quadrivalent, preservative|186 |Active|FLU|88 zoster recombinant|187 |Active|ZOSTER|188 zoster, unspecified formulation|188 |Inactive|ZOSTER|188 HepB-CpG|189 |Active|HepB|45 BCG|19 |Active|BCG|19 Hep A-Hep B, pediatric/adolescent|193 |Non-US|HepB|45 Hep A-Hep B, pediatric/adolescent|193 |Non-US|HepA|85 Influenza, Southern Hemisphere|194 |Inactive|FLU|88 DT, IPV adsorbed|195 |Non-US|Td|139 DT, IPV adsorbed|195 |Non-US|POLIO|89 Td, adsorbed, preservative free, adult use, Lf unspecified|196 |Active|Td|139 influenza, high-dose, quadrivalent|197 |Active|FLU|88 DTaP|20 |Active|DTAP|107 influenza, Southern Hemisphere, pediatric, preservative free|200 |Active|FLU|88 influenza, Southern Hemisphere, preservative free|201 |Active|FLU|88 influenza, Southern Hemisphere, quadrivalent, with preservative|202 |Active|FLU|88 meningococcal conjugate quadrivalent, MenACWY-TT (MCV4)|203 |Active|MENING|108 Ebola Zaire vaccine, live, recombinant, 1mL dose|204 |Active|Ebola|214 Influenza vaccine, quadrivalent, adjuvanted|205 |Active|FLU|88 Vaccinia, smallpox Mpox vaccine live, PF, SQ or ID injection|206 |Active|Orthopoxvirus|75 COVID-19, mRNA, LNP-S, PF, 100 mcg/0.5mL dose or 50 mcg/0.25mL dose|207 |Inactive|COVID-19|213 COVID-19, mRNA, LNP-S, PF, 30 mcg/0.3 mL dose|208 |Inactive|COVID-19|213 varicella|21 |Active|VARICELLA|21 COVID-19 vaccine, vector-nr, rS-ChAdOx1, PF, 0.5 mL|210 |Non-US|COVID-19|213 COVID-19, subunit, rS-nanoparticle+Matrix-M1 Adjuvant, PF, 0.5 mL|211 |Inactive|COVID-19|213 COVID-19 vaccine, vector-nr, rS-Ad26, PF, 0.5 mL|212 |Inactive|COVID-19|213 SARS-COV-2 (COVID-19) vaccine, UNSPECIFIED|213 |Inactive|COVID-19|213 Ebola, unspecified|214 |Inactive|Ebola|214 Pneumococcal conjugate PCV15, polysaccharide CRM197 conjugate, adjuvant, PF|215 |Active|PneumoPCV|152 Pneumococcal conjugate PCV20, polysaccharide CRM197 conjugate, adjuvant, PF|216 |Active|PneumoPCV|152 COVID-19, mRNA, LNP-S, PF, 30 mcg/0.3 mL dose, tris-sucrose|217 |Inactive|COVID-19|213 COVID-19, mRNA, LNP-S, PF, 10 mcg/0.2 mL dose, tris-sucrose|218 |Inactive|COVID-19|213 COVID-19, mRNA, LNP-S, PF, 3 mcg/0.2 mL dose, tris-sucrose|219 |Inactive|COVID-19|213 DTP-Hib|22 |Inactive|DTAP|107 DTP-Hib|22 |Inactive|HIB|17 HepB recombinant, 3-antigen, Al(OH)3|220 |Active|HepB|45 COVID-19, mRNA, LNP-S, PF, 50 mcg/0.5 mL dose|221 |Inactive|COVID-19|213 Tick-borne encephalitis, unspecified|222 |Inactive|Tick-borne encephalitis|222 Tick-borne encephalitis, inactivated, PF, 0.25mL|223 |Active|Tick-borne encephalitis|222 Tick-borne encephalitis, inactivated, PF, 0.5mL|224 |Active|Tick-borne encephalitis|222 COVID-19, D614, recomb, preS dTM, AS03 adjuvant add, PF, 5mcg/0.5mL|225 |Never Active|COVID-19|213 COVID-19, D614, recomb, preS dTM, AS03 adjuvant add, PF, 10mcg/0.5mL|226 |Never Active|COVID-19|213 COVID-19, mRNA, LNP-S, PF, pediatric 50 mcg/0.5 mL dose|227 |Inactive|COVID-19|213 COVID-19, mRNA, LNP-S, PF, pediatric 25 mcg/0.25 mL dose|228 |Inactive|COVID-19|213 COVID-19, mRNA, LNP-S, bivalent, PF, 50 mcg/0.5 mL or 25mcg/0.25 mL dose|229 |Inactive|COVID-19|213 plague|23 |Inactive|Plague|23 COVID-19, mRNA, LNP-S, bivalent, PF, 10 mcg/0.2 mL|230 |Inactive|COVID-19|213 influenza, Southern Hemisphere, high-dose, quadrivalent|231 |Active|FLU|88 Anthrax, pre-exposure prophylaxis, post-exposure prophylaxis|24 |Active|ANTHRAX|319 typhoid, oral|25 |Active|TYPHOID|91 cholera, unspecified formulation|26 |Inactive|cholera|26 DT (pediatric)|28 |Active|DTAP|107 COVID-19, mRNA, LNP-S, bivalent, PF, 30 mcg/0.3 mL dose|300 |Inactive|COVID-19|213 COVID-19, mRNA, LNP-S, bivalent, PF, 10 mcg/0.2 mL dose|301 |Inactive|COVID-19|213 COVID-19, mRNA, LNP-S, bivalent, PF, 3 mcg/0.2 mL dose|302 |Inactive|COVID-19|213 RSV, recombinant, protein subunit RSVpreF, adjuvant reconstituted, 0.5 mL, PF|303 |Active|RSV|304 Respiratory syncytial virus (RSV), unspecified|304 |Inactive|RSV|304 RSV, bivalent, protein subunit RSVpreF, diluent reconstituted, 0.5 mL, PF|305 |Active|RSV|304 RSV, mAb, nirsevimab-alip, 0.5 mL, neonate to 24 months|306 |Active|RSV|304 RSV, mAb, nirsevimab-alip, 1 mL, neonate to 24 months|307 |Active|RSV|304 COVID-19, mRNA, LNP-S, PF, tris-sucrose, 3 mcg/0.3 mL|308 |Active|COVID-19|213 COVID-19, mRNA, LNP-S, PF, tris-sucrose, 30 mcg/0.3 mL|309 |Active|COVID-19|213 Hep A, pediatric, unspecified formulation|31 |Inactive|HepA|85 COVID-19, mRNA, LNP-S, PF, tris-sucrose, 10 mcg/0.3 mL|310 |Active|COVID-19|213 COVID-19, mRNA, LNP-S, PF, 25 mcg/0.25 mL|311 |Active|COVID-19|213 COVID-19, mRNA, LNP-S, PF, 50 mcg/0.5 mL|312 |Active|COVID-19|213 COVID-19, subunit, rS-nanoparticle, adjuvanted, PF, 5 mcg/0.5 mL|313 |Active|COVID-19|213 Respiratory syncytial virus (RSV) vaccine, unspecified|314 |Inactive|RSV|304 Respiratory syncytial virus (RSV) MAB, unspecified|315 |Inactive|RSV|304 Meningococcal polysaccharide (MenACWY-TT conjugate), (MenB), PF|316 |Active|MENING|108 Meningococcal polysaccharide (MenACWY-TT conjugate), (MenB), PF|316 |Active|MeningB|164 Chikungunya live attenuated vaccine, 0.5 mL, PF|317 |Active|Chikungunya|317 Anthrax, post-exposure prophylaxis|318 |Active|ANTHRAX|319 Anthrax vaccine, unspecified|319 |Inactive|ANTHRAX|319 meningococcal MPSV4|32 |Inactive|MENING|108 pneumococcal polysaccharide PPV23|33 |Active|PneumoPPV|33 tetanus toxoid, adsorbed|35 |Inactive|Td|139 yellow fever live|37 |Active|YELLOWFEVER|184 rubella/mumps|38 |Inactive|MMR|03 Japanese encephalitis SC|39 |Inactive|Japanese encephalitis|129 rabies, intradermal injection|40 |Inactive|RABIES|90 typhoid, parenteral|41 |Inactive|TYPHOID|91 Hep B, adolescent/high risk infant|42 |Inactive|HepB|45 Hep B, adult|43 |Active|HepB|45 Hep B, dialysis|44 |Active|HepB|45 Hep B, unspecified formulation|45 |Inactive|HepB|45 Hib (PRP-D)|46 |Inactive|HIB|17 Hib (HbOC)|47 |Inactive|HIB|17 Hib (PRP-T)|48 |Active|HIB|17 Hib (PRP-OMP)|49 |Active|HIB|17 DTaP-Hib|50 |Inactive|DTAP|107 DTaP-Hib|50 |Inactive|HIB|17 COVID-19 Non-US Vaccine, Product Unknown|500 |Non-US|COVID-19|213 COVID-19 IV Non-US Vaccine (QAZCOVID-IN)|501 |Non-US|COVID-19|213 COVID-19 IV Non-US Vaccine (COVAXIN)|502 |Non-US|COVID-19|213 COVID-19 LAV Non-US Vaccine (COVIVAC)|503 |Non-US|COVID-19|213 COVID-19 VVnr Non-US Vaccine (Sputnik Light)|504 |Non-US|COVID-19|213 COVID-19 VVnr Non-US Vaccine (Sputnik V)|505 |Non-US|COVID-19|213 COVID-19 VVnr Non-US Vaccine (CanSino Biological Inc./Beijing Institute of Biotechnology|506 |Non-US|COVID-19|213 COVID-19 PS Non-US Vaccine (Anhui Zhifei Longcom Biopharm + Inst of Micro, Chinese Acad of Sciences)|507 |Non-US|COVID-19|213 COVID-19 PS Non-US Vaccine (Jiangsu Province Centers for Disease Control and Prevention)|508 |Non-US|COVID-19|213 COVID-19 PS Non-US Vaccine (EpiVacCorona)|509 |Non-US|COVID-19|213 Hib-Hep B|51 |Inactive|HIB|17 Hib-Hep B|51 |Inactive|HepB|45 COVID-19 IV Non-US Vaccine (BIBP, Sinopharm)|510 |Non-US|COVID-19|213 COVID-19 IV Non-US Vaccine (CoronaVac, Sinovac)|511 |Non-US|COVID-19|213 SARS-COV-2 COVID-19 VLP Non-US Vaccine (Medicago, Covifenz)|512 |Non-US|COVID-19|213 SARS-COV-2 COVID-19 PS Non-US Vaccine (Anhui Zhifei Longcom, Zifivax)|513 |Non-US|COVID-19|213 SARS-COV-2 COVID-19 DNA Non-US Vaccine (Zydus Cadila, ZyCoV-D)|514 |Non-US|COVID-19|213 SARS-COV-2 COVID-19 PS Non-US Vaccine (Medigen, MVC-COV1901)|515 |Non-US|COVID-19|213 COV-2 COVID-19 Inactivated Non-US Vaccine Product (Minhai Biotechnology Co, KCONVAC)|516 |Non-US|COVID-19|213 SARS-COV-2 COVID-19 PS Non-US Vaccine (Biological E Limited, Corbevax)|517 |Non-US|COVID-19|213 COVID-19 Inactivated, Non-US Vaccine (VLA2001, Valneva)|518 |Non-US|COVID-19|213 COVID-19 mRNA, bivalent, original/Omicron BA.1, Non-US Vaccine (Spikevax Bivalent), Moderna|519 |Non-US|COVID-19|213 Hep A, adult|52 |Active|HepA|85 COVID-19 mRNA, bivalent, original/Omicron BA.1, Non-US Vaccine Product, Pfizer-BioNTech|520 |Non-US|COVID-19|213 COVID-19 SP, protein-based, adjuvanted (VidPrevtyn Beta), Sanofi-GSK|521 |Non-US|COVID-19|213 typhoid, parenteral, AKD (U.S. military)|53 |Inactive|TYPHOID|91 adenovirus, type 4|54 |Inactive|ADENO|82 adenovirus, type 7|55 |Inactive|ADENO|82 dengue fever tetravalent|56 |Active|DENGUE|56 HPV, quadrivalent|62 |Active|HPV|137 Lyme disease|66 |Inactive|Lyme disease|66 rotavirus, tetravalent|74 |Inactive|ROTAVIRUS|122 vaccinia (smallpox)|75 |Active|Orthopoxvirus|75 Tick-borne encephalitis vaccine (non-US)|77 |Non-US|Tick-borne encephalitis|222 VEE, live|80 |Inactive|VEE|92 VEE, inactivated|81 |Inactive|VEE|92 adenovirus, unspecified formulation|82 |Inactive|ADENO|82 Hep A, ped/adol, 2 dose|83 |Active|HepA|85 Hep A, ped/adol, 3 dose|84 |Inactive|HepA|85 Hep A, unspecified formulation|85 |Inactive|HepA|85 influenza, unspecified formulation|88 |Inactive|FLU|88 polio, unspecified formulation|89 |Inactive|POLIO|89 rabies, unspecified formulation|90 |Inactive|RABIES|90 typhoid, unspecified formulation|91 |Inactive|TYPHOID|91 VEE, unspecified formulation|92 |Inactive|VEE|92 MMRV|94 |Active|MMR|03 MMRV|94 |Active|VARICELLA|21